In­un­dat­ed by de­mand, Gilead halts in­di­vid­ual emer­gency ac­cess to ex­per­i­men­tal Covid-19 drug

Slammed with a tidal wave of com­pas­sion­ate use re­quests, Gilead says it will have to put a halt to meet­ing in­di­vid­ual ap­peals for their coro­n­avirus drug remde­sivir while they fo­cus on wrap­ping a clin­i­cal tri­al to see if it works.

In re­cent days, the an­ti-malar­i­al drug chloro­quine and sim­i­lar drug hy­drox­y­chloro­quine have soaked up the spot­light as po­ten­tial “game-chang­ers” to com­bat the coro­n­avirus scourge that has en­veloped the globe. But Gilead’s an­tivi­ral remde­sivir was one of the first to be tout­ed as a po­ten­tial ther­a­py and is al­so one of the fur­thest along the path to­wards ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.